US3760806A - Helical osmotic dispenser with non-planar membrane - Google Patents
Helical osmotic dispenser with non-planar membrane Download PDFInfo
- Publication number
- US3760806A US3760806A US00106132A US3760806DA US3760806A US 3760806 A US3760806 A US 3760806A US 00106132 A US00106132 A US 00106132A US 3760806D A US3760806D A US 3760806DA US 3760806 A US3760806 A US 3760806A
- Authority
- US
- United States
- Prior art keywords
- compartment
- dispenser
- osmotic
- active agent
- perforated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 82
- 239000012528 membrane Substances 0.000 title description 25
- 239000013543 active substance Substances 0.000 claims abstract description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 230000004888 barrier function Effects 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 28
- -1 polyethylene Polymers 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 12
- 229920000573 polyethylene Polymers 0.000 claims description 12
- 239000004698 Polyethylene Substances 0.000 claims description 11
- 229920002301 cellulose acetate Polymers 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229920001971 elastomer Polymers 0.000 claims description 8
- 239000005060 rubber Substances 0.000 claims description 8
- 239000011521 glass Substances 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 239000012266 salt solution Substances 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 5
- 239000003822 epoxy resin Substances 0.000 claims description 5
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 5
- 229920000647 polyepoxide Polymers 0.000 claims description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 5
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 5
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- 229920002223 polystyrene Polymers 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 229910001369 Brass Inorganic materials 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 244000043261 Hevea brasiliensis Species 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000010951 brass Substances 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229920003052 natural elastomer Polymers 0.000 claims description 3
- 229920001206 natural gum Polymers 0.000 claims description 3
- 229920001194 natural rubber Polymers 0.000 claims description 3
- 229920001084 poly(chloroprene) Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 239000001120 potassium sulphate Substances 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229920002285 poly(styrene-co-acrylonitrile) Polymers 0.000 claims description 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 2
- 239000004945 silicone rubber Substances 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 29
- 230000035699 permeability Effects 0.000 abstract description 9
- 230000002035 prolonged effect Effects 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000003467 diminishing effect Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 description 10
- 238000010276 construction Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000005484 gravity Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001223 reverse osmosis Methods 0.000 description 4
- 210000004767 rumen Anatomy 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 231100000344 non-irritating Toxicity 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004100 Oxytetracycline Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960000625 oxytetracycline Drugs 0.000 description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
- 150000005011 4-aminoquinolines Chemical class 0.000 description 1
- 150000005012 8-aminoquinolines Chemical class 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 description 1
- GZHFODJQISUKAY-UHFFFAOYSA-N Methantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 GZHFODJQISUKAY-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- TUQLBJAHRWROHB-UHFFFAOYSA-N acetic acid;1-(1h-indol-3-yl)butan-2-amine Chemical compound CC(O)=O.C1=CC=C2C(CC(N)CC)=CNC2=C1 TUQLBJAHRWROHB-UHFFFAOYSA-N 0.000 description 1
- NMZSAMXFINECBQ-UHFFFAOYSA-N acetic acid;1-(1h-indol-3-yl)propan-2-amine Chemical compound CC([O-])=O.C1=CC=C2C(CC([NH3+])C)=CNC2=C1 NMZSAMXFINECBQ-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003619 algicide Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940055075 anticholinesterase parasympathomimetics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- OPNPQXLQERQBBV-UHFFFAOYSA-N carbromal Chemical compound CCC(Br)(CC)C(=O)NC(N)=O OPNPQXLQERQBBV-UHFFFAOYSA-N 0.000 description 1
- 229960001658 carbromal Drugs 0.000 description 1
- 229950009852 carfenazine Drugs 0.000 description 1
- TVPJGGZLZLUPOB-SPIKMXEPSA-N carphenazine maleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 TVPJGGZLZLUPOB-SPIKMXEPSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003996 chlormadinone Drugs 0.000 description 1
- VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-O codeine(1+) Chemical compound C([C@H]1[C@H]([NH+](CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-O 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- OVXQHPWHMXOFRD-UHFFFAOYSA-M ecothiopate iodide Chemical compound [I-].CCOP(=O)(OCC)SCC[N+](C)(C)C OVXQHPWHMXOFRD-UHFFFAOYSA-M 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229950002420 eucatropine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229950005360 hydroxyamfetamine Drugs 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004805 melengestrol Drugs 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001470 methantheline Drugs 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940100008 phospholine iodide Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 239000003128 rodenticide Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960003141 secobarbital sodium Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- AXXJTNXVUHVOJW-UHFFFAOYSA-M sodium;5-pentan-2-yl-5-prop-2-enylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC=C)C(=O)NC(=O)[N-]C1=O AXXJTNXVUHVOJW-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 description 1
- 229960004728 thiopropazate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 229960002485 trolnitrate Drugs 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/002—Forward osmosis or direct osmosis
- B01D61/0024—Controlling or regulating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/002—Forward osmosis or direct osmosis
- B01D61/005—Osmotic agents; Draw solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/04—Tubular membranes
Definitions
- the barrier member is slidably responsive to an increase in volume in the second compartment via absorption of water by osmosis therein; whereby as water flows into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving it into and diminishing the volume of the compartment 1 in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time.
- This invention relates to an osmotic dispenser, and, more especially, to an osmotic dispenser, simple in construction, capable of releasing to its outside environment concentrations of active agent at an osmotically controlled rate over a prolonged period of time.
- active agent denotes any drug (as defined, infra); composition in any way affecting any biological entity; substance having a nutrient or stimulating action, or growth inhibiting, destroying or any regulating action on plant growth, controlled or otherwise; substance to beassimilated by any organism, e.g., human being, animal, or lower order organism, for its nourishment or for regulating its growth; substance exhibiting any of the above activities to be directly applied to the habitat, surroundings or environment of any of the above organisms; and substance having any other effect on any other environement, especially: any aqueous environment.
- suitable active agents for use with the dispenser of this invention include, without limitation, those which are generally capable of:
- Controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or microorganism, such as food and non-food baits, attractants and lures, biocides, pesticides, algicides, parasiticides, rodenticides, insecticides, fungicides, and the like;
- Controlling or affecting generically an environment as by introducing a catalyst or metering a reactant into a reacting chemical system, or by effecting any chemical process therein, such as a fermentation, including propagation and/or attenuation of a microorganism.
- environment, surroundings and habitat denote any prospective situs for the osmotic dispenser of this invention which is comprised of or will provide sufficient water for absorption into the device to develop the needed osmotic pressure on which its motive'force depends; and implicit in the foregoing definition of active agent"-'- one that will develop its action in the presence of such environment, surroundings or habitat, or one that will develop its action in a remote and/or another environment, which need not be agueous, as hereinafter described and illustrated.
- compositions, products, appliances, depositors, applicators, dispensers, injectors and devices are well known in the art in which the timing or spacing of administration or absorption of an active agent is regulated by the structure or physical arrangement of elements so that a single administration provides a gradual but continuous or sustained feeding of the active agent to a system by slow or differential release. All of such prior art devices and the like, however, are characterized by at least one feature which adversely affects control over their rate of sustained or differential release or which detracts from the practical benefits attendant the long term continuous administration of various active agents both to humans, animals, and into other environments.
- the Rose et al. injector consists of three compartments and a clamp to hold a semi-permeable membrane.
- the motive force of the injector depends on the osmotic pressure developed by a saturated aqueous solution of Congo red against water.
- This solution is contained in a partially collapsed rubber compartment and is separated from a second water compartment by the semipermeable cellophane membrane.
- the partially collapsed bag is placed in a glass ampoule, with the drug compartment of the device being defined by thefspace between the Congo red bag and the glass ampoule.
- the ampoule is also provided with drug release means and when the drug compartment is charged with a drug solution, by osmosis water will move into the Congo red solution thus expanding the rubber compartment and providing the mechanical force to eject the drug out of the apparatus.
- the Rose et al, device however, has substantial inherent disadvantages which has prevented its wide acceptance by the medical community.
- the use of a solution as the drug vehicle 1. will not permit high concentration of drug to be embodied within the device; 2. such solutions exhibit the deleterious tendency to be released from the device by simple leaching, and 3. many chemical substances on prolonged storage in a dissolved state undergo chemical deterioration.
- the reference injector is moreover cumbersome in that it depends for its motive force on a separate water compartment rather than its environment.
- the Rose et a1 device is essentially only a research or experimentation tool, is complex in construction and is at least literally restricted to a Congo red solution to produce the osmotic driving force and to a cellophane osmotic membrane. See also Rose and Nelson, Austral. J. exp. Biol., 33 pp. 411 414 (1955).
- Another object of this invention is to provide an improved osmotic dispenser which overcomes problems inherent in related devices heretofore proposed.
- Another object of this invention is to provide an improved osomotic dispenser which will permit high concentrations of active agent to be embodied therein, and which high concentrations of active agent will not exhibit the tendency to be leached from the device, nor be decreased in potency by chemical breakdown.
- Another object of this invention is to provide an osmotic active agent dispenser which depends for its motive force on its environment.
- Still another object of this invention is to provide an osmotic dispenser, the osmotic membrane of which can be fabricated from many and varied suitable materials, and which is capable of using a variety of solutions of osmotically effective solutes to produce the osmotic driving force.
- Yet another object of this invention is to provide an osmotic dispenser of simple design which will release active agent solution, or gel, or semisolid active agent formulation, at a controlled rate over a prolonged period of time.
- an osmotic dispenser comprised of a first helical compartment of relatively impervious material containing an active agent and a second helical compartment containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water.
- the two helical compartments are interconnected so as to define a continuous helix. Separating the first helical compartment from the second helical compartment, and defining a wall member common to each of said compartments, is a sliding or movable barrier of impervious material, advantageously a plastic or glass ball separator.
- the enclosure is at least in part comprised of membrane material which exhibits controlled permeability to water.
- membrane material which exhibits controlled permeability to water.
- water by osmosis, is absorbed therefrom through the membrane and diffuses into the solution contained in the second compartment.
- the solution contained therein increases in volume exerting corresponding pressure behind the movable barrier divider.
- Such pressure serves to drive the said barrier forward and into the active agent compartment thus diminishing the volume of the same, and which sliding or rolling barrier in turn ejects the active agent out of the apparatus at an osmotically controlled rate over a prolonged period of time.
- the same is provided at its terminal point with any suitable dispensing head or active agent release means to the exterior of the device, for example, a capillary duct therethrough.
- a further feature of this invention resides in an osmotic active agent dispenser comprised of a dispenser according to the foregoing description enveloped by a relatively rigid, highly permeable housing member.
- the housing member serves both as a protective means for the dispenser and also to restrict expansion of the dispenser due to internal pressure. Alternatively, such expansion may be in and of itself restricted by means of any suitable band or tie member.
- FIG. 1 is a fragmentary cross-sectional view of an osmotic dispenser of this invention
- FIG. 2 is a top view of FIG. 1;
- FIG. 3 is a fragmentary cross-sectional view of a modification in the dispensing head of the osmotic dispenser of FIG. 1;
- FIG. 3a is a fragmentary cross-sectional view of another modification in the dispensing head of the os-' motic dispenser of FIG. 1;
- FIG. 4 is a fragmentary cross-sectional view of an osmotic dispenser of this invention having a rigid housing member.
- an osmotic dispenser 10 is comprised of two helically shaped compartments, a first compartment designated generally by reference numeral 12 and the second compartment designated by reference numeral 14.
- Each of the helical compartments is formed by coiling a relatively flexible tubular material, the former essentially being a continuation of the latter, although, as hereinafter described, there are significant differences in the types and properties of the tubular material used to fabricate each of the helical compartments l2 and 14.
- the lower end or terminal point of compartment 14 is sealed off, as, for example, by curved plug member 16 of a rigid impervious material such as refractory plastic.
- plug member 16 may be fabricated from metal or similar heavy material to additionally serve as a ballast member for adjusting the specific gravity of the dispenser.
- the terminal point of helical compartment 12 is provided with a short continuation in the form of tubing 18 having a capillary duct or opening 20 approximately 0.5 millimeters in diameter. Joints between the respective components may be press-fits or may involve use of an adhesive system.
- the device is preferably provided with one or more bands or ties 22 which bind together each of the coils in the helix and act as restraining means to prevent spreading of the coils due to internal pressures developed in the dispenser.
- a sliding barrier plug 24 of impermeable material compartmentalizes the helix and thus defines the exact boundaries of the helical compartments 12 and 14.
- the first compartment 12 contains the active agent, advantageously a drug, in a gel, paste or other semisolid state (albeit a solution or concentrated solution of active agent will sometimes suffice), and the active agent, if a drug, is preferably normally carried in an oil phase, such as cocoa butter.
- Compartment 12 is thus fabricated from a material which is impermeable both to the drug contained therein and also to all components of the dispenser environment.
- the second compartment 14 contains a solution of an osmotically efiective solute which exhibits an osmotic pressure gradient against water; and the sliding barrier plug 24 is so constructed as to movably provide and maintain a tight barrier between the active agent phase in the first compartment and the osmotic fluid in the second compartment.
- the barrier is a plastic or glass ball separator. Without this tight barrier, undesirable contamination could take place.
- Compartment 14 is fabricated at least in part from a material which exhibits controlled permeability to water, preferably a semi-permeable membrane of the type used in reverse osmosis water desalination, e.g., isotropic or anisotropic cellulose acetate. Obviously, the tubing used to fabricate compartment 14 must be impermeable to the osmotically active solute contained therein.
- the capillary tube or active agent release means 18 provides communication from the interior of the compartment 12 to the exterior of the device 10, in this instance the said means being comprised of capillary duct 20 formed at the tenninal point of the active agent containing helical compartment 12. See also FIG. 2.
- the plug 24 is frictionally disposed but is free to move within the device by sliding while at the same time maintaining an impenetrable or contamination preventing barrier between the active agent phase and the osmotic fluid.
- an oil/water or other interface can be said to exist at the point of the plug in the device.
- the device when the active agent is a drug or other agent for treating, etc., a living organism, is either physically inserted or surgically implanted in the body of the organism, typically a mammal, or is administered via the gastrointestinal tract. Once in place, water will be absorbed therein from either body tissues or body fluids through the water permeable walls of compartment 14 in an effort to reach osmotic equilibrium, i.e., a transition from hypertonicity to isotonicity. As the water flows into the compartment 14 tending to increase the volume of same corresponding pressure is built up behind the sliding barrier plug 24.
- Such pressure serves to drive the said barrier plug 24 forward at a constant rate thus forcing the drug through the tube 18 and capillary duct 20 at an osmotically controlled and constant rate into the external environment.
- the use of any semisolid drug vehicle will reduce the tendency to release the drug, or any other active agent for that matter, by leaching and will permit high concentrations thereof to be embodied within the device.
- the dispenser is of insufficient specific gravity to maintain placement at the desired location.
- the weight should be sufficient to provide a specific gravity of at least 1.5.
- a weight or ballast can be placed in the device, such as the metal plug 16 in FIG. 1. Suitable weights comprise steel plugs, iron plugs, brass plugs, ceramic plugs, or the like.
- the device When the active agent is other than a drug or similar agent, or is intended for use other than in a living organism, the device is introduced into the desired aqueous environment to produce the desired affect exactly as would be any of the known means for accomplishing v a like result. And this is generally a mere physical insertion, such as by placing a pesticide containing device in a river or stream or a catalyst containing device in an aqueous reaction medium.
- long flexible tubing of polythene or th like can be extended from the dispensing head of the device of FIG. I.
- the device can be deposited at a site remote from the desired point of application and still release its active agent contents through the dispensing head and then through the tube directly to said point.
- This permits placement of the dispenser in an aqueous environment and release of the active agent into another environment which need not be aqueous.
- the dispensing head can also be provided with a check valve, for example, a one way ball valve (see FIG. 3a), to prevent backflow of active agent or other materials from the external environment'into the device.
- the design of a device in accordance with the present invention is moreover unique in that it provides a simple means to control the amount of surface area available for osmotic penetration.
- a significant increase in the surface area of the water-permeable material results, whereby such a design provides for ready attainment of large exposure areas of the water permeable membrane and thus takes advantage of the availability of a far greater number of water-permeable materials than the semi-permeable, anisotropic cellulose acetate membrane of the type used in reverse osmosis water desalination.
- Isotropic membranes have less water permeability than do the anisotropic membranes. Use of the latter type of material, however, permits significant decreases in the size of helical compartment 14.
- FIG. 4 there is depicted an osmotic active agent dispenser generally of the type illustrated in FIG. 1, except that the same is enveloped by a relatively rigid permeable housing member 26.
- the porosity of the housing member readily permits contact of water from the environment with the dispensing device, while at the same time its relatively rigid characteristics afford a high degree of protection from damage or puncturing to the dispenser.
- the housing member advantageously serves as a restraining means to prevent spreading of the coils, etc., in the device due to internal pressure, especially when a housing member having both ends capped is provided for this purpose; and serves the furter purpose of facilitating emplacement in a given host or environment.
- the instant dispensing device may be designed to contain and administer any desired quantity of active agent to contain and administer any desired quantity of active agent by merely increasing or decreasing the length of tubing which constitutes the active agent containing helical compartment 12.
- a device according to this invention is admirably suited for the continuous administration of the antibiotic oxytetracycline to beef cattle from the rumen. This because such devices can easily be fabricated of a size, weight and shape as to be retained in the rumen of polygastric animals to release drug or similar agents thereto at a carefully controlled rate. Other variations of the basic theme would be readily apparent to the skilled artisan. Although particular configurations may be designed for specific body uses, each of these configurations is applicable to use in other environments.
- the tubing employed to fabricate the osmotic solution containing compartment 14 can be formed from the wide variety of materials permeable or semipermeable to solvent (water) but not to solute, i.e., those suitable for the construction of an osmotic cell.
- the material should be substantially impermeable to passage of the osmotically effective solute so as to prevent losses thereof. Same is also insoluble and chemically compatible with the salt solution in the compartment 14.
- Typical membranes are isotropic membranes such as unplasticized cellulose acetate, plasticized cellulose acetate, reinforced cellulose acetate, cellulose diand triacetate, ethyl cellulose; anisotropic reverse osmosis membranes which typically are made of cellulose acetate; silicone rubbers, polyurethanes, natural rubber, and hydrolyzed ethylene/vinyl acetate copolymers.
- Isotropic membranes such as above have less water permeability than do the anisotropic membranes. Also, with both types of materials, increasing the acetate content of the cellulose acetate polymer decreases the water permeability.
- the devices of this invention are not limited to any one class of water permeable material, i.e., both those exhibiting high permeability as well as those of lower permeability may be employed.
- a cellulose acetate membrane suitable for a device designed with limited surface area available for osmotic transfer is Eastman Chemical Products Type R 97, which is rated to be permeable to 1.5 to 2 cc/cm /day at atmospheric pressure, against a saturated solution of K 80 at 39 C.
- the compartment is fabricated from an anisotropic reverse osmosis type of membrane it is possible to obtain a delivery rate of from to 10,000 mg of active agent per day.
- the unplasticized membranes of whatever type provide for a far greater rate of release per day than do the plasticized membranes.
- the device of the above specific embodiment having a specific gravity of at least L5, is moreover well suited for administration to the rumen of beef cattle, whereat it is retained, via the gastrointestinal tract; and this is an excellent way of treating, for example, a 500 pound calf with anti-biotic.
- the membranes are also biologically inert, nonirritating to body tissues and non-allergenic.
- a dispenser fabricated in accordance with the design illustrated in FIG. 1, having compartment 14 fabricated of cellulose diacetate tubing (degree of acetyl substitution 2.4) and compartment 12 formed of polyethylene tubing, and having the following dimensions:
- Compartment l4 Compartment 12 Outer diameter of tubing 1.000 cm 0.976 cm Wall thickness 0.012 cm 0.050 cm Inner diameter of tubing 0.976 cm 0.876 cm Outer diameter of helix 3 cm 3 cm Number of turns 4 3 Uncoiled length 25.l cm 18.8 cm Initial volume Osmotic Solution l8.75 cc Saturated aqueous solution of NaCl containing sufficient excess solute in solid form to maintain solution saturated over period of intended use.
- the impermeable plastic material used to fabricate compartment 12 of the device too is insoluble, is chemically compatible with the active agent contained therein, and can be formed of polystyrene, polyethylene, polypropylene, polyethylene terephthalate, polyvinyl chloride, reinforced epoxy resin, polymethylmethacrylate, etc., metal foil polyethylene laminate, neoprene rubber, natural gum rubber, rubber hydrochloride, sheet metal, galvanized pipe, or styrene/acrylonitrile copolymer. It is of course intended that such casing or shell act as a barrier to the transport of water. Again, for drug depot applications, the same are advantageously biologically inert, non-irritating to body tissues and non-allergenic.
- the barrier plug 24 can be formed of materials identical to those used for fabricating the impervious active agent containing compartment 12, and additionally can be formed of glass. Likewise with respect to the rigid housing member 26 of FIG. 4, except in this instance the materials would be highly porous since it is not intended that the housing member in any way act as a barrier to or restrict the transport of water.
- the relative wall thicknesses of the various types of tubing comprising the two compartments of the dispeners of the invention can vary widely and are not limitations on the invention.
- the impermeable tubing of compartment 12 has a wall thickness of 0.5 to 50 mils, preferably of 5 to 50 mils
- the water permeable tubing of compartment 14 has a wall thickness of 1 to 10 mils.
- Drug used herein in its broadest sense as including any composition of substance that will produce a pharmacological or biological response.
- Suitable drugs for use in therapy with the dispenser of the invention include without limitation:
- Protein drugs such as insulin
- Desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen;
- Vaccines such as small pox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, dyphtheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influenzae, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc.;
- Anti-infectives such as antibiotics, including penicillin, tetracycline, chlortetracycline, bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate;
- antibiotics including penicillin, tetracycline, chlortetracycline, bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin
- Anti-allergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine;
- Anti-inflammatories such as hydrocortisone; cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2l-phosphate, fluocinolone, triamcinolone, .medrysone, prednisolone, prednisolone 2l-phosphate, and prednisolone acetate;
- Decongestants such as phenylephrine, naphazoline, and tetrahydrozoline;
- Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, di-isopropyl flurophosphate, phospholine iodide, and demercarium bromide;
- Mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine;
- Sedatives and Hypnotics such as pentobarbital sodium, phenobarbital, secobarbital sodium, codeine, (a-bromoisovaleryl) urea, carbromal;
- Psychic Energizers such as 3-(2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate:
- Tranquilizers such as reserpine, chlorpromazine, and thiopropazate;
- Estrogens such as estrone, l7 Bestradiol, and diethyl stilbesterol
- Progestational agents such as progesterone, megestrol, melengestrol, chlormadinone, ethisterone, norethynodrel, l9-nor-progesterone, norethindrone, medroxyprogesterone and 17 a-hydroxy-progesterone;
- Humoral agents such as the prostaglandins, for example, PGE PGE and PGF l8.
- Antipyretics such as aspirin, sodium salicylate, and salicylamide;
- Antispasmodics such as atropine, methantheline, papaverine, and methscopolamine bromide
- Anti-materials such as the 4-aminoquinolines, 8- aminoquinolines, chloroquine, and pyrimethamine;
- Antihistamines such as diphenhydramine, dimenhydrinate', tripelennamine, perphenazine, and carphenazine;
- Cardioactive agents such as hydrochlorothiazide, flumethiazide, chlorothiazide, and trolnitrate;
- Nutritional agents such as vitamins, essential 'amino acids and essential fats
- Suitable mixtures of drugs can, of course, be
- Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or non-irritating pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc.
- pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc.
- salts of metals, amines, or organic cations e.g., quaternary ammonium
- simple derivatives of the drugs such as ethers, esters, amides, etc.
- body pl-l, enzymes, etc. can be employed.
- the amount of drug incorporated in the osmotic dispenser varies widely depending on the particular drug, the desired therapeutic effect, and the time span for which it takes the drug to be released. Since a variety of dispensers in a variety of sizes and shapes are intended to provide complete dosage regimes for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the dispenser. The lower limit too will depend on the activity of the drug and the time span of its release from the dispenser. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the dispenser.
- the motive force of the dispenser of this invention depends on the osmotic pressure generated by the solution of the osmotically effective solute contained in the compartment 14, which solution exhibits an osmotic pressure gradient against water.
- Said solution is most preferably a saturated aqueous salt solution.
- the compartment containing the solution also contains excess solute in solid form.
- Various osmotically effective solutes can be used. These include magnesium sulphate, magnesium chloride, sodium -chloride, potassium sulphate, sodium carbonate, so-
- the excess solid solute can be in the I form of dispersed particles or preferably in the form of a pellet.
- the solution can initially be a solution of the same or of a osmotically effective solute different than the solid excess solute.
- the osmotic dispenser can be fabricated in any convenient shape for either physical insertion or implantation in the body, or for administration via the gastrointestinal tract, or for introduction into any desired environment. Dimensions of the device can thus vary widely and are not of controlling importance. The lower limit of the size of the device is governed by the amount of the particular active agent to be supplied to the environment to elicit the desired response, as well as by the form the dosage unit takes, for example, in
- the dispenser can be of such size as to deliver 1 to 2 cc of drug formulation per day and to deliver a total of 5 to cc of drug formulation over a 5 to 10 day period. With alternate choice of slower permeation materials, the pump can deliver drug more slowly up to and in excess of one year. It is preferred that the construction of the several compartments and of the active agent release means be such that the osmotic driving pressure developed is at least 10 times greater than the back pressure generated by the active agent formulation.
- the invention provides, in an osmotic dispenser, a reliable means for releasing effective concentrations of active agent contained therein to the body of a living organism, or to any other environment, at an osmotically controlled rate and over a prolonged period of time.
- prime advantages of the dispenser of the invention are that it is simple in construction and exhibits all of the practical advantages of the long-term continuous administration of various active agents both to humans, animals, and into other environments, and that the active agent contained therein will not exhibit the tendency to be leached therefrom.
- An osmotic active agent dispenser comprising, (1 a first helical compartment of relatively impervious material containing an active agent and provided with means for releasing said active agent to the exterior of the dispenser; (2) a second helical compartment comprised of membrane material having controlled permeability to water, being at least in part non-planar in configuration, and containing an osmotically effective solute which, in solution, exhibits an osmotic pressure gradient against water, said second compartment being interconnected with said first compartment to define a continuous helix therewith; means to restrict substantial expansion of the helix due to internal pressure and (3) a movable barrier member separating the said first from the said second compartment and movably responsive to an increase in volume in the said second compartment via absorption of water by osmosis therein; whereby as water flows into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving same into and diminishing the volume of the compartment l in turn continuously ejecting active agent
- the first helical compartment (1) is comprised of a member selected from the group consisting of polyethylene, metal-foil polyethylene laminate, neoprene rubber, rubber hydrochloride, polystyrene, polypropylene, polyethylene terephthalate, polyvinlyl chloride, polymethylmethacrylate, sheet metal, galvanized pipe, reinforced epoxy resin, natural gum rubber, and styreneacrylonitrile copolymer.
- the second helical compartment (2) is comprised of a member selected from the group consisting of cellulose acetate, silicone rubber, polyurethane, natural rubber and hydrolyzed ethylene/vinyl acetate copolymer.
- the active ingredient release means comprises a capillary tube forming an extension of helical compartment (1).
- the housing member is comprised of a member selected from the group consisting of perforated polystyrene, perforated polyethylene, perforated polypropylene, perforated polyethylene terephthalate, perforated polyvinyl chloride, perforated polymethylmethacrylate, perforated sheet metal, perforated reinforced epoxy resin, perforated galvanized pipe, porous sintered brass tubing, porous styrene/acrylonitrile polymer, and porous sintered polyethylene.
- osmotic dispenser as defined by claim 1, wherein the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulfite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate, magnesium succinate and mixtures thereof.
- the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulfite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate, magnesium succinate and mixtures thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Baking, Grill, Roasting (AREA)
- Medicinal Preparation (AREA)
Abstract
An osmotic active agent dispenser is comprised of: (1) a first helical compartment of relatively impervious material containing an active agent and provided with a dispensing head for releasing active agent to the exterior of the dispenser; (2) a second helical compartment of controlled permeability to water containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water, the second compartment being interconnected with said first compartment to define a continuous helix therewith; and (3) a movable barrier member separating the first from the second compartment. The barrier member is slidably responsive to an increase in volume in the second compartment via absorption of water by osmosis therein; whereby as water flows into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving it into and diminishing the volume of the compartment (1), in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time.
Description
Leeper I-IELICAL OSMOTIC DISPENSER WITH NON-PLANAR MEMBRANE [75] Inventor: Harold M. Leeper, Lawrence, Kans. g [73] Assignee: Alza Corporation, Palo Alto,
Calif.
[22] Filed: Jan. 13, 1971 [21] Appl. No.: 106,132
[52] US. Cl. 128/260, 128/130, 222/386 [51] Int. Cl. A61m 31/00, A61f 5/46 [58] Field of Search 128/260, 127-131, 128/172, 213, 261, 272, 271; 222/193, 389,
[56] References Cited UNITED STATES PATENTS 3,382,869 5/1968 Rigney et a1 128/130 3,604,417 9/1971 Stolzenberg 128/213 3,446,435 5/1969 Hager 222/389 X 2,962,023 11/1960 Chappaz et a1. 128/260 2,880,913 4/1959 Peyron 222/389 X 3,104,663 9/1963 Laws 128/224 [451 Sept. 25, 1973 Primary Examiner-Richard A. Gaudet Assistant ExaminerJ. C. McGowan Attorney-Steven D. Goldby and Paul L. Sabatine 5 7] ABSTRACT (3) a movable barrier member separating the first from I the second compartment. The barrier member is slidably responsive to an increase in volume in the second compartment via absorption of water by osmosis therein; whereby as water flows into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving it into and diminishing the volume of the compartment 1 in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time.
14 Claims, 5 Drawing Figures HELICAL OSMOTIC DISPENSER WITH NON-PLANAR MEMBRANE CROSS REFERENCE TO RELATED APPLICATIONS Takeru Higuchi copending application, Ser. No. 106,131, filed Jan. 13, 1971, assigned to the assignee of the present invention; and
Takeru l-liguchi and Harold M. Leeper copending application, Ser. No. 106,130, filed Jan. 13, 1971, also assigned to the assignee of the present invention.
FIELD OF THE INVENTION This invention relates to an osmotic dispenser, and, more especially, to an osmotic dispenser, simple in construction, capable of releasing to its outside environment concentrations of active agent at an osmotically controlled rate over a prolonged period of time.
DEFINITION OF TERMS The expression active agent as used herein denotes any drug (as defined, infra); composition in any way affecting any biological entity; substance having a nutrient or stimulating action, or growth inhibiting, destroying or any regulating action on plant growth, controlled or otherwise; substance to beassimilated by any organism, e.g., human being, animal, or lower order organism, for its nourishment or for regulating its growth; substance exhibiting any of the above activities to be directly applied to the habitat, surroundings or environment of any of the above organisms; and substance having any other effect on any other environement, especially: any aqueous environment.
Therefore, suitable active agents for use with the dispenser of this invention include, without limitation, those which are generally capable of:
l. Preventing, alleviating, treating or curing abnormal and pathological conditions of the living body by such means as destroying a parasitic organism or limit ing the effect of the disease or abnormality by chemicallyaltering the physiology of the host or parasite;
2. Maintaining, increasing, decreasing, limiting or destroying a physiologic body or plant function, e. g., vitamin compositions-sex sterilants, fertility inhibitors, fertility promoters, growth promoters, and the like;
3. Diagnosing a physiological condition or state;
. 4. Controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or microorganism, such as food and non-food baits, attractants and lures, biocides, pesticides, algicides, parasiticides, rodenticides, insecticides, fungicides, and the like;
5. Preserving, disinfecting or sterilizing; and
6. Controlling or affecting generically an environment, as by introducing a catalyst or metering a reactant into a reacting chemical system, or by effecting any chemical process therein, such as a fermentation, including propagation and/or attenuation of a microorganism.
The terms environment, surroundings and habitat as used hereinabove and herein denote any prospective situs for the osmotic dispenser of this invention which is comprised of or will provide sufficient water for absorption into the device to develop the needed osmotic pressure on which its motive'force depends; and implicit in the foregoing definition of active agent"-'- one that will develop its action in the presence of such environment, surroundings or habitat, or one that will develop its action in a remote and/or another environment, which need not be agueous, as hereinafter described and illustrated.
BACKGROUND OF THE INVENTION Many andva ried compositions, products, appliances, depositors, applicators, dispensers, injectors and devices are well known in the art in which the timing or spacing of administration or absorption of an active agent is regulated by the structure or physical arrangement of elements so that a single administration provides a gradual but continuous or sustained feeding of the active agent to a system by slow or differential release. All of such prior art devices and the like, however, are characterized by at least one feature which adversely affects control over their rate of sustained or differential release or which detracts from the practical benefits attendant the long term continuous administration of various active agents both to humans, animals, and into other environments.
An osmotic dispenser too has been proposed which is capable of delivering drug solution at a relatively constant rate. See Rose and Nelson, Austral, J. exp. BioL, 33 pp. 415 420 (1955). The Rose et al. injector consists of three compartments and a clamp to hold a semi-permeable membrane. The motive force of the injector depends on the osmotic pressure developed by a saturated aqueous solution of Congo red against water. This solution is contained in a partially collapsed rubber compartment and is separated from a second water compartment by the semipermeable cellophane membrane. The partially collapsed bag is placed in a glass ampoule, with the drug compartment of the device being defined by thefspace between the Congo red bag and the glass ampoule. The ampoule is also provided with drug release means and when the drug compartment is charged with a drug solution, by osmosis water will move into the Congo red solution thus expanding the rubber compartment and providing the mechanical force to eject the drug out of the apparatus.
The Rose et al, device, however, has substantial inherent disadvantages which has prevented its wide acceptance by the medical community. In the first place, the use of a solution as the drug vehicle 1. will not permit high concentration of drug to be embodied within the device; 2. such solutions exhibit the deleterious tendency to be released from the device by simple leaching, and 3. many chemical substances on prolonged storage in a dissolved state undergo chemical deterioration. The reference injector is moreover cumbersome in that it depends for its motive force on a separate water compartment rather than its environment. In addition, the Rose et a1, device is essentially only a research or experimentation tool, is complex in construction and is at least literally restricted to a Congo red solution to produce the osmotic driving force and to a cellophane osmotic membrane. See also Rose and Nelson, Austral. J. exp. Biol., 33 pp. 411 414 (1955).
SUMMARY OF THE INVENTION Accordingly, it is a primary object of this invention to provide an osmotic dispenser, simple in construction, which exhibits all of the practical benefits of longterm continuous administration of various active agents both to animals, humans, and into other environments.
Another object of this invention is to provide an improved osmotic dispenser which overcomes problems inherent in related devices heretofore proposed.
Another object of this invention is to provide an improved osomotic dispenser which will permit high concentrations of active agent to be embodied therein, and which high concentrations of active agent will not exhibit the tendency to be leached from the device, nor be decreased in potency by chemical breakdown.
Another object of this invention is to provide an osmotic active agent dispenser which depends for its motive force on its environment.
Still another object of this invention is to provide an osmotic dispenser, the osmotic membrane of which can be fabricated from many and varied suitable materials, and which is capable of using a variety of solutions of osmotically effective solutes to produce the osmotic driving force.
Yet another object of this invention is to provide an osmotic dispenser of simple design which will release active agent solution, or gel, or semisolid active agent formulation, at a controlled rate over a prolonged period of time.
In attaining the ob ects of this invention, one feature resides in an osmotic dispenser comprised of a first helical compartment of relatively impervious material containing an active agent and a second helical compartment containing a solution of an osmotically effective solute which exhibits an osmotic pressure gradient against water. The two helical compartments are interconnected so as to define a continuous helix. Separating the first helical compartment from the second helical compartment, and defining a wall member common to each of said compartments, is a sliding or movable barrier of impervious material, advantageously a plastic or glass ball separator. The enclosure, whether of integral construction or not, defining the remainder of the second compartment wherein the osmotic motive force of the dispenser is developed, is at least in part comprised of membrane material which exhibits controlled permeability to water. When placed in a hypotonic aqueous environment, water, by osmosis, is absorbed therefrom through the membrane and diffuses into the solution contained in the second compartment. As the water flows into the second compartment, the solution contained therein increases in volume exerting corresponding pressure behind the movable barrier divider. Such pressure serves to drive the said barrier forward and into the active agent compartment thus diminishing the volume of the same, and which sliding or rolling barrier in turn ejects the active agent out of the apparatus at an osmotically controlled rate over a prolonged period of time. For the purpose of permitting the active agent to be squeezed out of the first compartment, the same is provided at its terminal point with any suitable dispensing head or active agent release means to the exterior of the device, for example, a capillary duct therethrough.
A further feature of this invention resides in an osmotic active agent dispenser comprised of a dispenser according to the foregoing description enveloped by a relatively rigid, highly permeable housing member. The housing member serves both as a protective means for the dispenser and also to restrict expansion of the dispenser due to internal pressure. Alternatively, such expansion may be in and of itself restricted by means of any suitable band or tie member.
Other objects, features and advantages of this invention will become more apparent from the following description when taken in conjunction with the accompanying drawings and wherein like reference numerals are used to indicate like or equivalent parts.
BRIEF DESCRIPTION OF THE DRAWINGS In the drawings:
FIG. 1 is a fragmentary cross-sectional view of an osmotic dispenser of this invention;
FIG. 2 is a top view of FIG. 1;
FIG. 3 is a fragmentary cross-sectional view of a modification in the dispensing head of the osmotic dispenser of FIG. 1;
FIG. 3a is a fragmentary cross-sectional view of another modification in the dispensing head of the os-' motic dispenser of FIG. 1; and
FIG. 4 is a fragmentary cross-sectional view of an osmotic dispenser of this invention having a rigid housing member.
DETAILED DESCRIPTION OF THE INVENTION In one embodiment in accordance with this invention, as illustrated in FIG. 1, an osmotic dispenser 10 is comprised of two helically shaped compartments, a first compartment designated generally by reference numeral 12 and the second compartment designated by reference numeral 14. Each of the helical compartments is formed by coiling a relatively flexible tubular material, the former essentially being a continuation of the latter, although, as hereinafter described, there are significant differences in the types and properties of the tubular material used to fabricate each of the helical compartments l2 and 14. The lower end or terminal point of compartment 14 is sealed off, as, for example, by curved plug member 16 of a rigid impervious material such as refractory plastic. Optionally, plug member 16 may be fabricated from metal or similar heavy material to additionally serve as a ballast member for adjusting the specific gravity of the dispenser. The terminal point of helical compartment 12 is provided with a short continuation in the form of tubing 18 having a capillary duct or opening 20 approximately 0.5 millimeters in diameter. Joints between the respective components may be press-fits or may involve use of an adhesive system. The device is preferably provided with one or more bands or ties 22 which bind together each of the coils in the helix and act as restraining means to prevent spreading of the coils due to internal pressures developed in the dispenser. A sliding barrier plug 24 of impermeable material compartmentalizes the helix and thus defines the exact boundaries of the helical compartments 12 and 14.
The first compartment 12 contains the active agent, advantageously a drug, in a gel, paste or other semisolid state (albeit a solution or concentrated solution of active agent will sometimes suffice), and the active agent, if a drug, is preferably normally carried in an oil phase, such as cocoa butter. Compartment 12 is thus fabricated from a material which is impermeable both to the drug contained therein and also to all components of the dispenser environment.
The second compartment 14 contains a solution of an osmotically efiective solute which exhibits an osmotic pressure gradient against water; and the sliding barrier plug 24 is so constructed as to movably provide and maintain a tight barrier between the active agent phase in the first compartment and the osmotic fluid in the second compartment. Advantageously, and as illustrated, the barrier is a plastic or glass ball separator. Without this tight barrier, undesirable contamination could take place. Compartment 14 is fabricated at least in part from a material which exhibits controlled permeability to water, preferably a semi-permeable membrane of the type used in reverse osmosis water desalination, e.g., isotropic or anisotropic cellulose acetate. Obviously, the tubing used to fabricate compartment 14 must be impermeable to the osmotically active solute contained therein.
The capillary tube or active agent release means 18 provides communication from the interior of the compartment 12 to the exterior of the device 10, in this instance the said means being comprised of capillary duct 20 formed at the tenninal point of the active agent containing helical compartment 12. See also FIG. 2. The plug 24 is frictionally disposed but is free to move within the device by sliding while at the same time maintaining an impenetrable or contamination preventing barrier between the active agent phase and the osmotic fluid. Thus, an oil/water or other interface can be said to exist at the point of the plug in the device.
To use the osmotic active agent dispenser of FIG. 1, the device, when the active agent is a drug or other agent for treating, etc., a living organism, is either physically inserted or surgically implanted in the body of the organism, typically a mammal, or is administered via the gastrointestinal tract. Once in place, water will be absorbed therein from either body tissues or body fluids through the water permeable walls of compartment 14 in an effort to reach osmotic equilibrium, i.e., a transition from hypertonicity to isotonicity. As the water flows into the compartment 14 tending to increase the volume of same corresponding pressure is built up behind the sliding barrier plug 24. Such pressure serves to drive the said barrier plug 24 forward at a constant rate thus forcing the drug through the tube 18 and capillary duct 20 at an osmotically controlled and constant rate into the external environment. There is accordingly provided the gradual and controlled constant release of drug or similar agent directly to the body or affected organ thereof over a prolonged period of time. Moreover, the use of any semisolid drug vehicle will reduce the tendency to release the drug, or any other active agent for that matter, by leaching and will permit high concentrations thereof to be embodied within the device.
In some instances, the dispenser is of insufficient specific gravity to maintain placement at the desired location. For example, for use in the rumen of polygastric animals, the weight should be sufficient to provide a specific gravity of at least 1.5. In those instances of insufficient specific gravity, therefore, a weight or ballast can be placed in the device, such as the metal plug 16 in FIG. 1. Suitable weights comprise steel plugs, iron plugs, brass plugs, ceramic plugs, or the like.
' When the active agent is other than a drug or similar agent, or is intended for use other than in a living organism, the device is introduced into the desired aqueous environment to produce the desired affect exactly as would be any of the known means for accomplishing v a like result. And this is generally a mere physical insertion, such as by placing a pesticide containing device in a river or stream or a catalyst containing device in an aqueous reaction medium.
If desired, long flexible tubing of polythene or th like can be extended from the dispensing head of the device of FIG. I. In such a configuration, as illustrated in FIG. 3, the device can be deposited at a site remote from the desired point of application and still release its active agent contents through the dispensing head and then through the tube directly to said point. This permits placement of the dispenser in an aqueous environment and release of the active agent into another environment which need not be aqueous. The dispensing head can also be provided with a check valve, for example, a one way ball valve (see FIG. 3a), to prevent backflow of active agent or other materials from the external environment'into the device.
The design of a device in accordance with the present invention is moreover unique in that it provides a simple means to control the amount of surface area available for osmotic penetration. Thus, for example, by decreasing the diameter of the tubing used to manufacture the helical coils, or by increasing the number of turns in the helix of compartment 14 a significant increase in the surface area of the water-permeable material results, whereby such a design provides for ready attainment of large exposure areas of the water permeable membrane and thus takes advantage of the availability of a far greater number of water-permeable materials than the semi-permeable, anisotropic cellulose acetate membrane of the type used in reverse osmosis water desalination. Isotropic membranes have less water permeability than do the anisotropic membranes. Use of the latter type of material, however, permits significant decreases in the size of helical compartment 14.
In FIG. 4 there is depicted an osmotic active agent dispenser generally of the type illustrated in FIG. 1, except that the same is enveloped by a relatively rigid permeable housing member 26. The porosity of the housing member readily permits contact of water from the environment with the dispensing device, while at the same time its relatively rigid characteristics afford a high degree of protection from damage or puncturing to the dispenser. Moreover, the housing member advantageously serves as a restraining means to prevent spreading of the coils, etc., in the device due to internal pressure, especially when a housing member having both ends capped is provided for this purpose; and serves the furter purpose of facilitating emplacement in a given host or environment.
Another salient feature of the osmotic active agent dispenser of this invention resides in its simple means of construction, and correlatively in the simple manner thereby provided for controlling the dosage rate in a given dispenser device. In contradistinction to other known types of active agent dispensing devices wherein a device of different size is required for each dosage level to be contained therein, the instant dispensing device may be designed to contain and administer any desired quantity of active agent to contain and administer any desired quantity of active agent by merely increasing or decreasing the length of tubing which constitutes the active agent containing helical compartment 12.
Moreover, a device according to this invention is admirably suited for the continuous administration of the antibiotic oxytetracycline to beef cattle from the rumen. This because such devices can easily be fabricated of a size, weight and shape as to be retained in the rumen of polygastric animals to release drug or similar agents thereto at a carefully controlled rate. Other variations of the basic theme would be readily apparent to the skilled artisan. Although particular configurations may be designed for specific body uses, each of these configurations is applicable to use in other environments.
The tubing employed to fabricate the osmotic solution containing compartment 14 can be formed from the wide variety of materials permeable or semipermeable to solvent (water) but not to solute, i.e., those suitable for the construction of an osmotic cell. For best results, the material should be substantially impermeable to passage of the osmotically effective solute so as to prevent losses thereof. Same is also insoluble and chemically compatible with the salt solution in the compartment 14. Typical membranes are isotropic membranes such as unplasticized cellulose acetate, plasticized cellulose acetate, reinforced cellulose acetate, cellulose diand triacetate, ethyl cellulose; anisotropic reverse osmosis membranes which typically are made of cellulose acetate; silicone rubbers, polyurethanes, natural rubber, and hydrolyzed ethylene/vinyl acetate copolymers. Isotropic membranes such as above have less water permeability than do the anisotropic membranes. Also, with both types of materials, increasing the acetate content of the cellulose acetate polymer decreases the water permeability. Since, as previously described, the surface area available for osmotic transfer may be widely varied, the devices of this invention are not limited to any one class of water permeable material, i.e., both those exhibiting high permeability as well as those of lower permeability may be employed. Thus, a cellulose acetate membrane suitable for a device designed with limited surface area available for osmotic transfer is Eastman Chemical Products Type R 97, which is rated to be permeable to 1.5 to 2 cc/cm /day at atmospheric pressure, against a saturated solution of K 80 at 39 C. When the compartment is fabricated from an anisotropic reverse osmosis type of membrane it is possible to obtain a delivery rate of from to 10,000 mg of active agent per day. In genera], the unplasticized membranes of whatever type provide for a far greater rate of release per day than do the plasticized membranes. The device of the above specific embodiment, having a specific gravity of at least L5, is moreover well suited for administration to the rumen of beef cattle, whereat it is retained, via the gastrointestinal tract; and this is an excellent way of treating, for example, a 500 pound calf with anti-biotic. For drug depot applications as heretofore described, the membranes are also biologically inert, nonirritating to body tissues and non-allergenic. One specific embodiment of a dispenser fabricated in accordance with the design illustrated in FIG. 1, having compartment 14 fabricated of cellulose diacetate tubing (degree of acetyl substitution 2.4) and compartment 12 formed of polyethylene tubing, and having the following dimensions:
Diameter 3.2 cm Height 7.5 cm
Approximately 55 percent oxytetracycline hydrochloride in 45 percent cocoa butter medium.
is capable of delivering 20 to 300 mg of drug per day.
The impermeable plastic material used to fabricate compartment 12 of the device too is insoluble, is chemically compatible with the active agent contained therein, and can be formed of polystyrene, polyethylene, polypropylene, polyethylene terephthalate, polyvinyl chloride, reinforced epoxy resin, polymethylmethacrylate, etc., metal foil polyethylene laminate, neoprene rubber, natural gum rubber, rubber hydrochloride, sheet metal, galvanized pipe, or styrene/acrylonitrile copolymer. It is of course intended that such casing or shell act as a barrier to the transport of water. Again, for drug depot applications, the same are advantageously biologically inert, non-irritating to body tissues and non-allergenic. The barrier plug 24 can be formed of materials identical to those used for fabricating the impervious active agent containing compartment 12, and additionally can be formed of glass. Likewise with respect to the rigid housing member 26 of FIG. 4, except in this instance the materials would be highly porous since it is not intended that the housing member in any way act as a barrier to or restrict the transport of water.
Many other materials including those which are biologically acceptable are suitable for fabrication of the several component parts of the device of this invention. While the said several component parts of the device of the invention have previously been described as being insoluble under the conditions and in the environment of intended use, it is also within the scope of the invention that such materials be insoluble only during the period of said intended use; thereafter dissolving away in the environment of the device. Thus, a dispenser is here contemplated which is unaffected by its environment, solubility-wise, at the situs of use, or which is only slightly soluble during the period of intended use, such that once its active agent content has been discharged it will then dissolve or erode away leaving no objectionable residue or empty container at the said situs of use.
It is further within the scope of the invention to optionally provide the subject dispenser with a selfcontained water supply or separate water compartment, as in the first mentioned Rose and Nelson publication, supra.
The relative wall thicknesses of the various types of tubing comprising the two compartments of the dispeners of the invention can vary widely and are not limitations on the invention. Typically, however, the impermeable tubing of compartment 12 has a wall thickness of 0.5 to 50 mils, preferably of 5 to 50 mils, and the water permeable tubing of compartment 14 has a wall thickness of 1 to 10 mils.
Any of the drugs used to treat the body, both topical and systemic, can be compartmentalized as the active agent in any of the osmotic dispensers of this invention. Drug" is used herein in its broadest sense as including any composition of substance that will produce a pharmacological or biological response.
Suitable drugs for use in therapy with the dispenser of the invention include without limitation:
1. Protein drugs such as insulin;
2. Desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen;
3. Vaccines such as small pox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, dyphtheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influenzae, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc.;
4. Anti-infectives, such as antibiotics, including penicillin, tetracycline, chlortetracycline, bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate;
5. Anti-allergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine;
6. Anti-inflammatories such as hydrocortisone; cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2l-phosphate, fluocinolone, triamcinolone, .medrysone, prednisolone, prednisolone 2l-phosphate, and prednisolone acetate;
7. Decongestants such as phenylephrine, naphazoline, and tetrahydrozoline;
8. Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, di-isopropyl flurophosphate, phospholine iodide, and demercarium bromide;
9. Mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine;
l0. Sympathomimetics such as epinephrine;
ll. Sedatives and Hypnotics such as pentobarbital sodium, phenobarbital, secobarbital sodium, codeine, (a-bromoisovaleryl) urea, carbromal;
l2. Psychic Energizers such as 3-(2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate:
l3. Tranquilizers such as reserpine, chlorpromazine, and thiopropazate;
l4. Androgenic steroids such as methyltestosterone and fluoxymesterone;
l5. Estrogens such as estrone, l7 Bestradiol, and diethyl stilbesterol;
l6. Progestational agents such as progesterone, megestrol, melengestrol, chlormadinone, ethisterone, norethynodrel, l9-nor-progesterone, norethindrone, medroxyprogesterone and 17 a-hydroxy-progesterone;
l7. Humoral agents such as the prostaglandins, for example, PGE PGE and PGF l8. Antipyretics such as aspirin, sodium salicylate, and salicylamide;
l9. Antispasmodics such as atropine, methantheline, papaverine, and methscopolamine bromide;
20. Anti-materials such as the 4-aminoquinolines, 8- aminoquinolines, chloroquine, and pyrimethamine;
21. Antihistamines such as diphenhydramine, dimenhydrinate', tripelennamine, perphenazine, and carphenazine;
22. Cardioactive agents such as hydrochlorothiazide, flumethiazide, chlorothiazide, and trolnitrate;
23. Nutritional agents such as vitamins, essential 'amino acids and essential fats;
vention. Suitable mixtures of drugs can, of course, be
dispensed with equal facility as with single component systems.
Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or non-irritating pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc. For acidic drugs, salts of metals, amines, or organic cations (e.g., quaternary ammonium) can be employed. Furthermore, simple derivatives of the drugs (such as ethers, esters, amides, etc.) which have desirable retention and release characteristics but which are easily hydrolyzed by body pl-l, enzymes, etc., can be employed.
The amount of drug incorporated in the osmotic dispenser varies widely depending on the particular drug, the desired therapeutic effect, and the time span for which it takes the drug to be released. Since a variety of dispensers in a variety of sizes and shapes are intended to provide complete dosage regimes for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the dispenser. The lower limit too will depend on the activity of the drug and the time span of its release from the dispenser. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the dispenser.
The motive force of the dispenser of this invention depends on the osmotic pressure generated by the solution of the osmotically effective solute contained in the compartment 14, which solution exhibits an osmotic pressure gradient against water. Said solution is most preferably a saturated aqueous salt solution. To maintain the solution saturated and therefore to achieve a constant osmotic pressure throughout operation of the dispenser, the compartment containing the solution also contains excess solute in solid form. Various osmotically effective solutes can be used. These include magnesium sulphate, magnesium chloride, sodium -chloride, potassium sulphate, sodium carbonate, so-
dium sulphite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate, and magnesium succinate. The excess solid solute can be in the I form of dispersed particles or preferably in the form of a pellet. The solution can initially be a solution of the same or of a osmotically effective solute different than the solid excess solute.
The osmotic dispenser can be fabricated in any convenient shape for either physical insertion or implantation in the body, or for administration via the gastrointestinal tract, or for introduction into any desired environment. Dimensions of the device can thus vary widely and are not of controlling importance. The lower limit of the size of the device is governed by the amount of the particular active agent to be supplied to the environment to elicit the desired response, as well as by the form the dosage unit takes, for example, in
cases of specific body uses, implantate, bolus, IUD, lVD, vaginal ring, uterine capsule for fertility suppression, artificial gland, pessary, prosthesis, suppository, and the like. Likewise with respect to the upper limit on the size of the device. In one specific embodiment, the dispenser can be of such size as to deliver 1 to 2 cc of drug formulation per day and to deliver a total of 5 to cc of drug formulation over a 5 to 10 day period. With alternate choice of slower permeation materials, the pump can deliver drug more slowly up to and in excess of one year. It is preferred that the construction of the several compartments and of the active agent release means be such that the osmotic driving pressure developed is at least 10 times greater than the back pressure generated by the active agent formulation.
Thus, the invention provides, in an osmotic dispenser, a reliable means for releasing effective concentrations of active agent contained therein to the body of a living organism, or to any other environment, at an osmotically controlled rate and over a prolonged period of time. In addition, prime advantages of the dispenser of the invention are that it is simple in construction and exhibits all of the practical advantages of the long-term continuous administration of various active agents both to humans, animals, and into other environments, and that the active agent contained therein will not exhibit the tendency to be leached therefrom.
While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various modifications, changes, omissions, and substitutions can be made without departing from the spirit of the invention. It is intended, therefore, that the invention be limited only by the scope of the following claims.
What is claimed is:
1. An osmotic active agent dispenser comprising, (1 a first helical compartment of relatively impervious material containing an active agent and provided with means for releasing said active agent to the exterior of the dispenser; (2) a second helical compartment comprised of membrane material having controlled permeability to water, being at least in part non-planar in configuration, and containing an osmotically effective solute which, in solution, exhibits an osmotic pressure gradient against water, said second compartment being interconnected with said first compartment to define a continuous helix therewith; means to restrict substantial expansion of the helix due to internal pressure and (3) a movable barrier member separating the said first from the said second compartment and movably responsive to an increase in volume in the said second compartment via absorption of water by osmosis therein; whereby as water flows into the compartment (2) of the dispenser in a tendency towards osmotic equilibrium with its environment, corresponding pressure is exerted behind the barrier (3) driving same into and diminishing the volume of the compartment l in turn continuously ejecting active agent thereout at an osmotically controlled rate over a prolonged period of time.
2. The osmotic dispenser as defined by claim 1, wherein the barrer (3) defines a wall member common to each of said compartments (1) and (2).
3. The osmotic dispenser as defined by claim 1, wherein the active agent is selected from the group consisting of a drug and a bio-affecting composition.
4. The osmotic dispenser as defined by claim 1, wherein the active agent contained therein is in the form of a semisolid formulation.
5. The osmotic dispenser as defined by claim 1, wherein the solution exhibiting an osmotic pressure gradient against water is a saturated aqueous salt solution.
6. The osmotic dispenser as defined by claim 5, wherein the saturated salt solution contains excess solute in solid form.
7. The osmotic dispenser as defined by claim 1, wherein the first helical compartment (1) is comprised of a member selected from the group consisting of polyethylene, metal-foil polyethylene laminate, neoprene rubber, rubber hydrochloride, polystyrene, polypropylene, polyethylene terephthalate, polyvinlyl chloride, polymethylmethacrylate, sheet metal, galvanized pipe, reinforced epoxy resin, natural gum rubber, and styreneacrylonitrile copolymer.
8. The osmotic dispenser as defined by claim 1, wherein the second helical compartment (2) is comprised of a member selected from the group consisting of cellulose acetate, silicone rubber, polyurethane, natural rubber and hydrolyzed ethylene/vinyl acetate copolymer.
9. The osmotic dispenser as defined by claim 1, wherein the active ingredient release means comprises a capillary tube forming an extension of helical compartment (1).
10. The osmotic dispenser as defined by claim 1, wherein the restricting means comprises a relatively rigid permeable housing member enveloping the device.
11. The osmotic dispenser as defined by claim 10, wherein the housing member is comprised of a member selected from the group consisting of perforated polystyrene, perforated polyethylene, perforated polypropylene, perforated polyethylene terephthalate, perforated polyvinyl chloride, perforated polymethylmethacrylate, perforated sheet metal, perforated reinforced epoxy resin, perforated galvanized pipe, porous sintered brass tubing, porous styrene/acrylonitrile polymer, and porous sintered polyethylene.
12. The osmotic dispenser as defined by claim 1, wherein the movable impervious barrier is a spherical body comprised of glass or plastic.
13. The osmotic dispenser as defined by claim 1, further comprising a ballast member to regulate the weight thereof.
14. The osmotic dispenser as defined by claim 1, wherein the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulfite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate, magnesium succinate and mixtures thereof.
Claims (13)
- 2. The osmotic dispenser as defined by claim 1, wherein the barrer (3) defines a wall member common to each of said compartments (1) and (2).
- 3. The osmotic dispenser as defined by claim 1, wherein the active agent is selected from the group consisting of a drug and a bio-affecting composition.
- 4. The osmotic dispenser as defined by claim 1, wherein the active agent contained therein is in the form of a semisolid formulation.
- 5. The osmotic dispenser as defined by claim 1, wherein the solution exhibiting an osmotic pressure gradient against water is a saturated aqueous salt solution.
- 6. The osmotic dispenser as defined by claim 5, wherein the saturated salt solution contains excess solute in solid form.
- 7. The osmotic dispenser as defined by claim 1, wherein the first helical compartment (1) is comprised of a member selected from the group consisting of polyethylene, metal-foil polyethylene laminate, neoprene rubber, rubber hydrochloride, polystyrene, polypropylene, polyethylene terephthalate, polyvinlyl chloride, polymethylmethacrylate, sheet metal, galvanized pipe, reinforced epoxy resin, natural gum rubber, and styreneacrylonitrile copolymer.
- 8. The osmotic dispenser as defined by claim 1, wherein the second helical compartment (2) is comprised of a member selected from the group consisting of cellulose acetate, silicone rubber, polyurethane, natural rubber and hydrolyzed ethylene/vinyl acetate copolymer.
- 9. The osmotic dispenser as defined by claim 1, wherein the active ingredient release means comprises a capillary tube forming an extension of helical compartment (1).
- 10. The osmotic dispenser as defined by claim 1, wherein the restricting means comprises a relatively rigid permeable housing member enveloping the device.
- 11. The osmotic dispenser as defined by claim 10, wherein the housing member is comprised of a member selected from the group consisting of perforated polystyrene, perforated polyethylene, perforated polypropylene, perforated polyethylene terephthalate, perforated polyvinyl chloride, perforated polymethylmethacrylate, perforated sheet metal, perforated reinforced epoxy resin, perforated galvanized pipe, porous sintered brass tubing, porous styrene/acrylonitrile polymer, and porous sintered polyethylene.
- 12. The osmotic dispenser as defined by claim 1, wherein the movable impervious barrier is a spherical body comprised of glass or plastic.
- 13. The osmotic dispenser as defined by claim 1, further comprising a ballast member to regulate the weight thereof.
- 14. The osmotic dispenser as defined by claim 1, wherein the osmotically effective solute is selected from the group consisting of magnesium sulphate, magnesium chloride, sodium chloride, potassium sulphate, sodium carbonate, sodium sulfite, sodium sulphate, sodium bicarbonate, potassium acid phthalate, calcium bicarbonate, potassium acid phosphate, raffinose, tartaric acid, succinic acid, calcium succinate, calcium lactate, magnesium succinate and mixtures thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10613271A | 1971-01-13 | 1971-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3760806A true US3760806A (en) | 1973-09-25 |
Family
ID=22309665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US00106132A Expired - Lifetime US3760806A (en) | 1971-01-13 | 1971-01-13 | Helical osmotic dispenser with non-planar membrane |
Country Status (2)
Country | Link |
---|---|
US (1) | US3760806A (en) |
JP (1) | JPS4894575A (en) |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3880164A (en) * | 1972-05-22 | 1975-04-29 | Alza Corp | Osmotic wound drain |
US4034756A (en) * | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
US4036227A (en) * | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4177256A (en) * | 1973-04-25 | 1979-12-04 | Alza Corporation | Osmotic bursting drug delivery device |
US4243030A (en) * | 1978-08-18 | 1981-01-06 | Massachusetts Institute Of Technology | Implantable programmed microinfusion apparatus |
EP0179518A1 (en) * | 1984-10-16 | 1986-04-30 | Akzo N.V. | IUD extractor thread |
US4662879A (en) * | 1984-09-15 | 1987-05-05 | Stc Plc | Rumen bolus |
US4680172A (en) * | 1985-03-05 | 1987-07-14 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4765985A (en) * | 1985-03-05 | 1988-08-23 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
US4871542A (en) * | 1987-04-30 | 1989-10-03 | Ferring Service Center, N.V. | Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract |
US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5299581A (en) * | 1990-07-05 | 1994-04-05 | Donnell John T | Intravaginal device |
US5308348A (en) * | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5456679A (en) * | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
US5582591A (en) * | 1994-09-02 | 1996-12-10 | Delab | Delivery of solid drug compositions |
US5660846A (en) * | 1994-09-02 | 1997-08-26 | Societe De Conseils De Recherches Et D'applications Scientifiques | Methods and apparatus for the delivery of solid drug compositions |
US5897530A (en) * | 1997-12-24 | 1999-04-27 | Baxter International Inc. | Enclosed ambulatory pump |
US5972369A (en) * | 1997-03-31 | 1999-10-26 | Alza Corporation | Diffusional implantable delivery system |
US6114347A (en) * | 1993-12-10 | 2000-09-05 | Lts Lohmann Therapie-Systeme Gmbh | Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors |
US6136013A (en) * | 1996-09-18 | 2000-10-24 | Owen Mumford Limited | Lancet device |
US6554792B2 (en) * | 1999-05-21 | 2003-04-29 | Mallinckrodt Inc. | Suspension device and method |
US6627631B1 (en) * | 1999-02-19 | 2003-09-30 | Lts Lohmann Therapie-Systeme Ag | Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism |
US20030191453A1 (en) * | 2002-04-03 | 2003-10-09 | Velez Omar E. | Catheter assembly |
US20040159324A1 (en) * | 1995-06-07 | 2004-08-19 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and their delivery |
US20040260271A1 (en) * | 2003-06-18 | 2004-12-23 | Huyser Richard F. | Extended fenestration catheter with internal coil and method of making the same |
US20040260242A1 (en) * | 1999-05-21 | 2004-12-23 | Mallinckrodt Inc. | Suspension device and method |
US20050175701A1 (en) * | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
US20050172972A1 (en) * | 1995-06-07 | 2005-08-11 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and methods |
US20070023534A1 (en) * | 2005-07-22 | 2007-02-01 | Mingsheng Liu | Water-source heat pump control system and method |
US20070149954A1 (en) * | 2005-11-09 | 2007-06-28 | Searete Llc., A Limited Liability Corporation Of The State Of Delaware | Acoustically controlled substance delivery device |
US20080140057A1 (en) * | 2006-03-09 | 2008-06-12 | Searete Llc, A Limited Liability Corporation Of State Of The Delaware | Injectable controlled release fluid delivery system |
US20080177126A1 (en) * | 2007-01-01 | 2008-07-24 | Tate Leon J | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
US20090005727A1 (en) * | 2006-03-09 | 2009-01-01 | Searete Llc | Acoustically controlled substance delivery device |
US20090162249A1 (en) * | 2006-03-09 | 2009-06-25 | Searete Llc | Acoustically controlled reaction device |
US20100030185A1 (en) * | 2006-01-18 | 2010-02-04 | Searete Llc | Remote controller for substance delivery system |
US20100076415A1 (en) * | 2005-11-09 | 2010-03-25 | Searete Llc | Remote control of substance delivery system |
GB2446100B (en) * | 2005-11-09 | 2011-11-02 | Searete Llc | Remote controlled in vivo reaction method |
US8109923B2 (en) | 2005-12-13 | 2012-02-07 | The Invention Science Fund I, Llc | Osmotic pump with remotely controlled osmotic pressure generation |
US20120203264A1 (en) * | 2011-01-21 | 2012-08-09 | Endologix, Inc. | Graft Systems Having Semi-Permeable Filling Structures and Methods for Their Use |
WO2013064745A1 (en) * | 2011-11-01 | 2013-05-10 | Bayer Oy | Osmotically active vaginal delivery system |
US9067047B2 (en) | 2005-11-09 | 2015-06-30 | The Invention Science Fund I, Llc | Injectable controlled release fluid delivery system |
US9108047B2 (en) | 2010-06-04 | 2015-08-18 | Bayer Medical Care Inc. | System and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors |
US9296757B2 (en) | 2012-05-21 | 2016-03-29 | Bayer Pharma Aktiengesellschaft | Substituted benzothienopyrimidines |
US9382255B2 (en) | 2012-09-20 | 2016-07-05 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5836370Y2 (en) * | 1981-01-13 | 1983-08-16 | 公明 中川 | Giyoza grill machine |
JPH0483135U (en) * | 1990-11-29 | 1992-07-20 | ||
JP2002223950A (en) * | 2001-01-29 | 2002-08-13 | Owada Seisakusho:Kk | Machine and cooking method for spit-roasting |
ITUD20110159A1 (en) * | 2011-10-07 | 2013-04-08 | M E G I C Pizza Ciacolada S A S D I Acampora Ger | DEVICE FOR THE FORMING AND COOKING OF A FOAMED OVEN FOOD PRODUCT, FILLED PIZZA TYPE |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2880913A (en) * | 1957-05-31 | 1959-04-07 | Francois A Peyron | Tubes for dispensing pastes, creams and the like |
US2962023A (en) * | 1955-10-28 | 1960-11-29 | Chappaz Gaston | Medicator |
US3104663A (en) * | 1960-02-03 | 1963-09-24 | Birch And Birch | Pressurized means for body cavity treatment |
US3382869A (en) * | 1966-02-02 | 1968-05-14 | Ortho Pharma Corp | Intrauterine contraceptive device |
US3446435A (en) * | 1967-06-19 | 1969-05-27 | Moog Inc | Expulsion device having floating piston |
US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
-
1971
- 1971-01-13 US US00106132A patent/US3760806A/en not_active Expired - Lifetime
-
1972
- 1972-02-24 JP JP47018556A patent/JPS4894575A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2962023A (en) * | 1955-10-28 | 1960-11-29 | Chappaz Gaston | Medicator |
US2880913A (en) * | 1957-05-31 | 1959-04-07 | Francois A Peyron | Tubes for dispensing pastes, creams and the like |
US3104663A (en) * | 1960-02-03 | 1963-09-24 | Birch And Birch | Pressurized means for body cavity treatment |
US3382869A (en) * | 1966-02-02 | 1968-05-14 | Ortho Pharma Corp | Intrauterine contraceptive device |
US3446435A (en) * | 1967-06-19 | 1969-05-27 | Moog Inc | Expulsion device having floating piston |
US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
Non-Patent Citations (1)
Title |
---|
Govidan and Sourirajan, Reverse Osmosis Separation of Some Inorganic Salts ... Using...Membranes; I & EC Process Design and Development, Vol. 5, No. 4, Oct. 1966; p. 422 429. * |
Cited By (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4034756A (en) * | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
US3880164A (en) * | 1972-05-22 | 1975-04-29 | Alza Corp | Osmotic wound drain |
US4036227A (en) * | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
US4177256A (en) * | 1973-04-25 | 1979-12-04 | Alza Corporation | Osmotic bursting drug delivery device |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4243030A (en) * | 1978-08-18 | 1981-01-06 | Massachusetts Institute Of Technology | Implantable programmed microinfusion apparatus |
US4662879A (en) * | 1984-09-15 | 1987-05-05 | Stc Plc | Rumen bolus |
EP0179518A1 (en) * | 1984-10-16 | 1986-04-30 | Akzo N.V. | IUD extractor thread |
US4680172A (en) * | 1985-03-05 | 1987-07-14 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
US4765985A (en) * | 1985-03-05 | 1988-08-23 | Ciba-Geigy Corporation | Devices and methods for treating memory impairment |
US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4871542A (en) * | 1987-04-30 | 1989-10-03 | Ferring Service Center, N.V. | Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract |
US5299581A (en) * | 1990-07-05 | 1994-04-05 | Donnell John T | Intravaginal device |
US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5308348A (en) * | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5456679A (en) * | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
US6114347A (en) * | 1993-12-10 | 2000-09-05 | Lts Lohmann Therapie-Systeme Gmbh | Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors |
US5660846A (en) * | 1994-09-02 | 1997-08-26 | Societe De Conseils De Recherches Et D'applications Scientifiques | Methods and apparatus for the delivery of solid drug compositions |
US5582591A (en) * | 1994-09-02 | 1996-12-10 | Delab | Delivery of solid drug compositions |
US5837276A (en) * | 1994-09-02 | 1998-11-17 | Delab | Apparatus for the delivery of elongate solid drug compositions |
US6306420B1 (en) | 1994-09-02 | 2001-10-23 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Methods and apparatus for the delivery of solid drug compositions |
US6142972A (en) * | 1994-09-02 | 2000-11-07 | Delab | Method and apparatus for the delivery of elongate solid drug compositions |
US5616123A (en) * | 1994-09-02 | 1997-04-01 | Delab | Delivery of solid drug compositions |
US8171936B2 (en) | 1995-06-07 | 2012-05-08 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and methods |
US20050172972A1 (en) * | 1995-06-07 | 2005-08-11 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and methods |
US8733361B2 (en) | 1995-06-07 | 2014-05-27 | Bayer Essure Inc. | Occlusion devices and methods |
US20070062542A1 (en) * | 1995-06-07 | 2007-03-22 | Nikolchev Julian N | Contraceptive transcervical fallopian tube occlusion devices and methods |
US8356599B2 (en) | 1995-06-07 | 2013-01-22 | Conceptus, Inc. | Occlusion devices and methods |
US8327852B2 (en) | 1995-06-07 | 2012-12-11 | Conceptus, Inc. | Occlusion devices and methods |
US20040163651A1 (en) * | 1995-06-07 | 2004-08-26 | Conceptus, Inc. | Transcervical fallopian tube occlusion devices and their delivery |
US7428904B2 (en) | 1995-06-07 | 2008-09-30 | Alien Technology Corporation | Contraceptive transcervical fallopian tube occlusion devices and their delivery |
US20040159324A1 (en) * | 1995-06-07 | 2004-08-19 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and their delivery |
US8066007B2 (en) | 1995-06-07 | 2011-11-29 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and their delivery |
US7921848B2 (en) | 1995-06-07 | 2011-04-12 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and methods |
US7686020B2 (en) | 1995-06-07 | 2010-03-30 | Conceptus, Inc. | Contraceptive transcervical fallopian tube occlusion devices and methods |
US6136013A (en) * | 1996-09-18 | 2000-10-24 | Owen Mumford Limited | Lancet device |
US5972369A (en) * | 1997-03-31 | 1999-10-26 | Alza Corporation | Diffusional implantable delivery system |
US8613282B2 (en) | 1997-09-24 | 2013-12-24 | Conceptus, Inc. | Occlusion devices and methods |
US8733360B2 (en) | 1997-09-24 | 2014-05-27 | Bayer Essure Inc. | Occlusion devices and methods |
US5897530A (en) * | 1997-12-24 | 1999-04-27 | Baxter International Inc. | Enclosed ambulatory pump |
US6627631B1 (en) * | 1999-02-19 | 2003-09-30 | Lts Lohmann Therapie-Systeme Ag | Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism |
US6554792B2 (en) * | 1999-05-21 | 2003-04-29 | Mallinckrodt Inc. | Suspension device and method |
US20030105423A1 (en) * | 1999-05-21 | 2003-06-05 | Mallinckrodt Inc. | Suspension device and method |
US20040260242A1 (en) * | 1999-05-21 | 2004-12-23 | Mallinckrodt Inc. | Suspension device and method |
US20030191453A1 (en) * | 2002-04-03 | 2003-10-09 | Velez Omar E. | Catheter assembly |
US20040260271A1 (en) * | 2003-06-18 | 2004-12-23 | Huyser Richard F. | Extended fenestration catheter with internal coil and method of making the same |
WO2005077334A1 (en) * | 2004-02-10 | 2005-08-25 | Alza Corporation | Capillary moderator in an osmotic delivery system for preventing backflow into the active agent reservoir |
US20050175701A1 (en) * | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
US20070023534A1 (en) * | 2005-07-22 | 2007-02-01 | Mingsheng Liu | Water-source heat pump control system and method |
US8998884B2 (en) | 2005-11-09 | 2015-04-07 | The Invention Science Fund I, Llc | Remote controlled in situ reaction method |
US9254256B2 (en) | 2005-11-09 | 2016-02-09 | The Invention Science Fund I, Llc | Remote controlled in vivo reaction method |
US8992511B2 (en) | 2005-11-09 | 2015-03-31 | The Invention Science Fund I, Llc | Acoustically controlled substance delivery device |
US8968274B2 (en) | 2005-11-09 | 2015-03-03 | The Invention Science Fund I, Llc | Acoustically controlled substance delivery device |
US8114065B2 (en) | 2005-11-09 | 2012-02-14 | The Invention Science Fund I, Llc | Remote control of substance delivery system |
US8172833B2 (en) | 2005-11-09 | 2012-05-08 | The Invention Science Fund I, Llc | Remote control of substance delivery system |
US20100076415A1 (en) * | 2005-11-09 | 2010-03-25 | Searete Llc | Remote control of substance delivery system |
US8936590B2 (en) | 2005-11-09 | 2015-01-20 | The Invention Science Fund I, Llc | Acoustically controlled reaction device |
US9474712B2 (en) | 2005-11-09 | 2016-10-25 | Gearbox, Llc | In situ reaction device |
US8906000B2 (en) | 2005-11-09 | 2014-12-09 | The Invention Science Fund I, Llc | Injectable controlled release fluid delivery system |
US8882747B2 (en) | 2005-11-09 | 2014-11-11 | The Invention Science Fund I, Llc | Substance delivery system |
US9028467B2 (en) | 2005-11-09 | 2015-05-12 | The Invention Science Fund I, Llc | Osmotic pump with remotely controlled osmotic pressure generation |
GB2446100B (en) * | 2005-11-09 | 2011-11-02 | Searete Llc | Remote controlled in vivo reaction method |
US9067047B2 (en) | 2005-11-09 | 2015-06-30 | The Invention Science Fund I, Llc | Injectable controlled release fluid delivery system |
US8617141B2 (en) | 2005-11-09 | 2013-12-31 | The Invention Science Fund I, Llc | Remote controlled in situ reaction device |
US20070149954A1 (en) * | 2005-11-09 | 2007-06-28 | Searete Llc., A Limited Liability Corporation Of The State Of Delaware | Acoustically controlled substance delivery device |
US8529551B2 (en) | 2005-11-09 | 2013-09-10 | The Invention Science Fund I, Llc | Acoustically controlled substance delivery device |
US8568388B2 (en) | 2005-11-09 | 2013-10-29 | The Invention Science Fund I, Llc | Remote controlled in situ reaction device |
US8585684B2 (en) | 2005-11-09 | 2013-11-19 | The Invention Science Fund I, Llc | Reaction device controlled by magnetic control signal |
US8998886B2 (en) | 2005-12-13 | 2015-04-07 | The Invention Science Fund I, Llc | Remote control of osmotic pump device |
US8273075B2 (en) | 2005-12-13 | 2012-09-25 | The Invention Science Fund I, Llc | Osmotic pump with remotely controlled osmotic flow rate |
US8192390B2 (en) | 2005-12-13 | 2012-06-05 | The Invention Science Fund I, Llc | Method and system for control of osmotic pump device |
US8109923B2 (en) | 2005-12-13 | 2012-02-07 | The Invention Science Fund I, Llc | Osmotic pump with remotely controlled osmotic pressure generation |
US20100030185A1 (en) * | 2006-01-18 | 2010-02-04 | Searete Llc | Remote controller for substance delivery system |
US8273071B2 (en) | 2006-01-18 | 2012-09-25 | The Invention Science Fund I, Llc | Remote controller for substance delivery system |
US20090005727A1 (en) * | 2006-03-09 | 2009-01-01 | Searete Llc | Acoustically controlled substance delivery device |
US8367003B2 (en) | 2006-03-09 | 2013-02-05 | The Invention Science Fund I, Llc | Acoustically controlled reaction device |
US20090162249A1 (en) * | 2006-03-09 | 2009-06-25 | Searete Llc | Acoustically controlled reaction device |
US20080140057A1 (en) * | 2006-03-09 | 2008-06-12 | Searete Llc, A Limited Liability Corporation Of State Of The Delaware | Injectable controlled release fluid delivery system |
US8349261B2 (en) | 2006-03-09 | 2013-01-08 | The Invention Science Fund, I, LLC | Acoustically controlled reaction device |
US8083710B2 (en) | 2006-03-09 | 2011-12-27 | The Invention Science Fund I, Llc | Acoustically controlled substance delivery device |
US9056164B2 (en) * | 2007-01-01 | 2015-06-16 | Bayer Medical Care Inc. | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
US9913941B2 (en) | 2007-01-01 | 2018-03-13 | Bayer Healthcare Llc | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
US20080177126A1 (en) * | 2007-01-01 | 2008-07-24 | Tate Leon J | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
US9108047B2 (en) | 2010-06-04 | 2015-08-18 | Bayer Medical Care Inc. | System and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors |
US9463335B2 (en) | 2010-06-04 | 2016-10-11 | Bayer Healthcare Llc | System and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors |
US20120203264A1 (en) * | 2011-01-21 | 2012-08-09 | Endologix, Inc. | Graft Systems Having Semi-Permeable Filling Structures and Methods for Their Use |
US8801768B2 (en) * | 2011-01-21 | 2014-08-12 | Endologix, Inc. | Graft systems having semi-permeable filling structures and methods for their use |
WO2013064745A1 (en) * | 2011-11-01 | 2013-05-10 | Bayer Oy | Osmotically active vaginal delivery system |
CN103974742A (en) * | 2011-11-01 | 2014-08-06 | 拜尔公司 | Osmotically active vaginal delivery system |
US20140309598A1 (en) * | 2011-11-01 | 2014-10-16 | Bayer Oy | Osmotically active vaginal delivery system |
EA026830B1 (en) * | 2011-11-01 | 2017-05-31 | Байер Ой | Osmotically active vaginal delivery system |
AU2012330960B2 (en) * | 2011-11-01 | 2017-06-29 | Bayer Oy | Osmotically active vaginal delivery system |
TWI615155B (en) * | 2011-11-01 | 2018-02-21 | 拜耳股份有限公司 | Osmotically active vaginal delivery system |
US9296757B2 (en) | 2012-05-21 | 2016-03-29 | Bayer Pharma Aktiengesellschaft | Substituted benzothienopyrimidines |
US9382255B2 (en) | 2012-09-20 | 2016-07-05 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JPS4894575A (en) | 1973-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3760806A (en) | Helical osmotic dispenser with non-planar membrane | |
US3760805A (en) | Osmotic dispenser with collapsible supply container | |
US3732865A (en) | Osmotic dispenser | |
US3995631A (en) | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient | |
US3760804A (en) | Improved osmotic dispenser employing magnesium sulphate and magnesium chloride | |
US4034756A (en) | Osmotically driven fluid dispenser | |
US3995632A (en) | Osmotic dispenser | |
US3929132A (en) | Osmotic dispenser | |
US3760984A (en) | Osmotically powered agent dispensing device with filling means | |
US3840009A (en) | Self-powered vapor pressure delivery device | |
US4439194A (en) | Water and drug delivery system for suppository use | |
US5017381A (en) | Multi-unit pulsatile delivery system | |
EP0266929B1 (en) | Stressed polymeric device for controlled release of a substance to an ambient environment | |
US5429822A (en) | Biodegradable bursting release system | |
US4601893A (en) | Laminate device for controlled and prolonged release of substances to an ambient environment and method of use | |
AU595033B2 (en) | Pulsatile drug delivery system | |
KR0183058B1 (en) | Osmotic device for delayed delivery of drugs | |
JP2659932B2 (en) | Transdermal and transmucosal drug applicators | |
EP0153070B1 (en) | Laminate device for controlled and prolonged release of substances to an ambient environment | |
US6569152B2 (en) | Sustained release delivery systems for solutes | |
US4751071A (en) | Composition comprising salbutamol | |
JPS6210205B2 (en) | ||
DE2247949A1 (en) | DEVICE FOR ADMINISTRATION OF MEDICINAL PRODUCTS | |
DE2201533A1 (en) | Osmotic device for the application of active agents | |
DK143318B (en) | OSMOTIC DISPENSES |